Fig. 2
From: JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
Expression of JAK1 and JAK2 and their association with prognosis in colorectal cancer. Representative images of negative, weak, moderate and strong IHC staining for JAK1 and JAK2 proteins in a retrospective cohort of CRC patients (A). Histograms showing the distribution of weighted histoscores for cytoplasmic JAK1 (B) and JAK2 (C). Representative images of high and low tumor stromal percentage cases (D). Kaplan Meier survival curve showing the association between TSP and CSS in cohort 1 (E). Kaplan Meier survival analysis of JAK1 and JAK2 tumor membrane expression in TSPhigh cases in cohort 1 (F). Kaplan Meier survival analysis of membranous JAK1 and JAK2 expression in TSPhigh cases when each protein was assessed individually (G-H). Representative staining of HCT116 cell pellets stained for pSTAT3tyr705 via IHC after treatment with vehicle of AZD1480 (I). Dose response curve showing the effect of JAK specific inhibitor AZD1480 on HCT116 cell viability (H). Bar chart showing the effect of 100µM AZD1480 on cell viability of mouse model organoids when used as monotherapy in AKPT (p = 0.056) and KPN (p < 0.0001) and in combination with 100µM 5FU (AKPT p = 0.002, KPN p = 0.0006) (I). Significance set to p < 0.05*, p < 0.005**, p < 0.0005***